Glial cell line-derived neurotrophic factor (GDNF) potently promotes axonal regeneration after peripheral nerve injury, but persistent local overexpression traps regenerating axons at the GDNF source (the 'candy-store' effect), preventing long-distance regeneration and target reinnervation. A 2013 proof-of-principle study by Shakhbazau and colleagues showed that doxycycline-regulated, time-restricted GDNF expression from transplanted Schwann cells avoids trapping and improves recovery, yet left the central question open: what temporal profile of GDNF expression maximizes regeneration and functional recovery without entrapment. The study separately listed the signaling pathways through which GDNF acts and clinically translatable delivery as open companion directions. A decade of follow-up work has validated the principle of timed expression, developed immune-evasive gene switches, and produced scattered, model-specific duration comparisons, but no study or synthesis has established an optimal regimen; the conflicting optima reported across injury models motivate characterizing how any optimum depends on injury geometry, and the entrapment mechanism remains unresolved. Reviews through 2026 still name GDNF dosing as an unsolved challenge.

Background

Peripheral nerve injuries are repaired surgically (direct reapproximation or grafting across a gap), but regeneration is slow and functional recovery, especially over long distances, remains poor. Neurotrophic factors are attractive adjuncts: glial cell line-derived neurotrophic factor (GDNF), a secreted protein that signals through the GFRalpha1 co-receptor and the RET receptor tyrosine kinase (and can also signal through the neural cell adhesion molecule NCAM), is a potent survival and axon-growth factor for motor neurons and nociceptive sensory neurons. However, sustained high local GDNF causes a striking pathology first systematized by Tannemaat et al. (2008): regenerating motor axons stop, coil, and branch abundantly at the GDNF source instead of continuing to their targets, a trapping effect dubbed the 'candy-store' effect, which abolishes the benefit of the factor. Because GDNF is short-lived in tissue, gene therapy (viral-vector-mediated expression) is the practical delivery route, and the trapping problem then becomes a problem of expression control. Regulatable expression systems, such as tetracycline-dependent transactivators that turn a transgene on or off in response to the orally available antibiotic doxycycline, permit the timing and duration of GDNF production to be set experimentally. Shakhbazau et al. (2013) engineered Schwann cells (the glial cells that support regenerating axons) with a lentiviral doxycycline-regulated GDNF vector, transplanted them into transected rat sciatic nerve, and showed that one week of GDNF induction followed by deactivation increased axonal regeneration and prevented the axonal misdirection seen with continuous expression, with improved recovery of thermal sensitivity. The study itself listed what it did not establish: the optimal timing and duration of GDNF expression were unknown (one week on, two weeks off was a first guess, not an optimum); the signaling pathways mediating the benefit and the trapping were not investigated; the non-viral dendrimer delivery route was too inefficient for in vivo use; the tetracycline transactivator is immunogenic in vivo; and no large-animal validation or clinical dosing/safety framework existed. Later work has built the toolbox for each strand: immune-evasive ('stealth') tetracycline transactivators (Hoyng et al. 2014), alternative regulated systems such as Cre-lox excision of the GDNF transgene (Wu-Fienberg et al. 2014) and tetracycline-regulated c-Jun control of multiple neurotrophic factors (Huang et al. 2019), in vitro microfluidic models of entrapment showing concentration dependence (Wang et al. 2018), evidence that entrapment has a Schwann-cell/extracellular-matrix component independent of GDNF's direct action on axons (Ee et al. 2017), timed-GDNF validation in ventral root avulsion models (Eggers et al. 2019), a duration comparison (4, 6, or 8 weeks) in a long-gap model (Marquardt et al. 2015), and sustained-release GDNF conduits tested in nonhuman primates (Fadia et al. 2020). Yet these results also show the problem is not closed: reported useful durations range from one week to six weeks depending on model and expression level, trapping still occurs in a substantial fraction of animals under some timed regimens, and the mechanism of entrapment remains only partially understood.

Problem Statement

Establish a temporally optimized regimen of GDNF expression for peripheral nerve repair. Specifically, in the rat sciatic-nerve transection/repair model of Shakhbazau et al. (2013), treated with a regulatable GDNF gene-therapy system (e.g., doxycycline-inducible GDNF expressed from transplanted Schwann cells or a viral vector), determine the timing, duration, level, and spatial placement of GDNF expression that maximizes axonal regeneration and functional sensory and motor recovery while avoiding entrapment of regenerating axons at the GDNF source: timing is the onset of GDNF induction in days after nerve injury; duration is the length of the induction window in days; level is the local GDNF concentration to which regenerating axons are exposed (in an explicit unit, e.g., ng/mL or fold-change over endogenous); and spatial placement is the signed position of the GDNF source along the nerve relative to the lesion and the distal target. Entrapment — the coiling or branching of regenerating axons at the GDNF source — must be avoided: it is a hard requirement on the regimen, not a quantity traded off against regeneration or recovery. These four parameters are jointly required, and it must additionally be determined whether and how this optimum shifts when injury geometry such as gap length and distance to target is varied.

The related strands that the source study listed among its limitations remain recognized follow-on directions rather than conjunctive completion requirements of the dosing question above: the signaling pathways mediating the regenerative benefit and the trapping were not investigated, and no large-animal validation or clinical dosing/safety framework existed.

References

  1. Shakhbazau A, Mohanty C, Shcharbin D, Bryszewska M, Caminade A-M, Majoral J-P, Alant J, Midha R. Doxycycline-regulated GDNF expression promotes axonal regeneration and functional recovery in transected peripheral nerve. Journal of Controlled Release 172(3):841-851, 2013. DOI: 10.1016/j.jconrel.2013.10.004. https://doi.org/10.1016/j.jconrel.2013.10.004
  2. Tannemaat MR, Eggers R, Hendriks WT, de Ruiter GC, van Heerikhuize JJ, Pool CW, Malessy MJ, Boer GJ, Verhaagen J. Differential effects of lentiviral vector-mediated overexpression of nerve growth factor and glial cell line-derived neurotrophic factor on regenerating sensory and motor axons in the transected peripheral nerve. European Journal of Neuroscience 28(8):1467-1479, 2008. DOI: 10.1111/j.1460-9568.2008.06452.x. https://doi.org/10.1111/j.1460-9568.2008.06452.x
  3. Hoyng SA, Gnavi S, de Winter F, Eggers R, Ozawa T, Zaldumbide A, Hoeben RC, Malessy MJ, Verhaagen J. Developing a potentially immunologically inert tetracycline-regulatable viral vector for gene therapy in the peripheral nerve. Gene Therapy 21(6):549-557, 2014. DOI: 10.1038/gt.2014.22. https://doi.org/10.1038/gt.2014.22
  4. Wu-Fienberg Y, Moore AM, Marquardt LM, Newton P, Johnson PJ, Mackinnon SE, Sakiyama-Elbert SE, Wood MD. Viral transduction of primary Schwann cells using a Cre-lox system to regulate GDNF expression. Biotechnology and Bioengineering 111(9):1886-1894, 2014. DOI: 10.1002/bit.25247. https://doi.org/10.1002/bit.25247
  5. Pajenda G, Hercher D, Marton G, Pajer K, Feichtinger GA, Maleth J, Redl H, Nogradi A. Spatiotemporally limited BDNF and GDNF overexpression rescues motoneurons destined to die and induces elongative axon growth. Experimental Neurology 261:367-376, 2014. DOI: 10.1016/j.expneurol.2014.05.019. https://doi.org/10.1016/j.expneurol.2014.05.019
  6. Marquardt LM, Ee X, Iyer N, Hunter D, Mackinnon SE, Wood MD, Sakiyama-Elbert SE. Finely tuned temporal and spatial delivery of GDNF promotes enhanced nerve regeneration in a long nerve defect model. Tissue Engineering Part A 21(23-24):2852-2864, 2015. DOI: 10.1089/ten.tea.2015.0311. https://doi.org/10.1089/ten.tea.2015.0311
  7. Ee X, Yan Y, Hunter DA, Schellhardt L, Sakiyama-Elbert SE, Mackinnon SE, Wood MD. Transgenic SCs expressing GDNF-IRES-DsRed impair nerve regeneration within acellular nerve allografts. Biotechnology and Bioengineering 114(9):2121-2130, 2017. DOI: 10.1002/bit.26335. https://doi.org/10.1002/bit.26335
  8. Wang ZZ, Wood MD, Mackinnon SE, Sakiyama-Elbert SE. A microfluidic platform to study the effects of GDNF on neuronal axon entrapment. Journal of Neuroscience Methods 308:183-191, 2018. DOI: 10.1016/j.jneumeth.2018.08.002. https://doi.org/10.1016/j.jneumeth.2018.08.002
  9. Eggers R, de Winter F, Hoyng SA, Hoeben RC, Malessy MJA, Tannemaat MR, Verhaagen J. Timed GDNF gene therapy using an immune-evasive gene switch promotes long distance axon regeneration. Brain 142(2):295-311, 2019. DOI: 10.1093/brain/awy340. https://doi.org/10.1093/brain/awy340
  10. Eggers R, de Winter F, Arkenaar C, Tannemaat MR, Verhaagen J. Enhanced regeneration and reinnervation following timed GDNF gene therapy in a cervical ventral root avulsion. Experimental Neurology 321:113037, 2019. DOI: 10.1016/j.expneurol.2019.113037. https://doi.org/10.1016/j.expneurol.2019.113037
  11. Huang L, Xia B, Shi X, Gao J, Yang Y, Xu F, Qi F, Liang C, Huang J, Luo Z. Time-restricted release of multiple neurotrophic factors promotes axonal regeneration and functional recovery after peripheral nerve injury. The FASEB Journal 33(7):8600-8613, 2019. DOI: 10.1096/fj.201802065RR. https://doi.org/10.1096/fj.201802065RR
  12. Eggers R, de Winter F, Smit L, Luimens M, Muir EM, Bradbury EJ, Tannemaat MR, Verhaagen J. Combining timed GDNF and ChABC gene therapy to promote long-distance regeneration following ventral root avulsion and repair. The FASEB Journal 34(8):10605-10622, 2020. DOI: 10.1096/fj.202000559R. https://doi.org/10.1096/fj.202000559R
  13. Eggers R, de Winter F, Tannemaat MR, Malessy MJA, Verhaagen J. GDNF gene therapy to repair the injured peripheral nerve. Frontiers in Bioengineering and Biotechnology 8:583184, 2020. DOI: 10.3389/fbioe.2020.583184. https://doi.org/10.3389/fbioe.2020.583184
  14. Fadia NB, Bliley JM, DiBernardo GA, Crammond DJ, Schilling BK, Sivak WN, Spiess AM, Washington KM, Waldner M, Liao HT, James IB, Minteer DM, Tompkins-Rhoades C, Cottrill AR, Kim DY, Schweizer R, Bourne DA, Panagis GE, Schusterman MA 2nd, Egro FM, Campwala IK, Simpson T, Weber DJ, Gause T 2nd, Brooker JE, Josyula T, Guevara AA, Repko AJ, Mahoney CM, Marra KG. Long-gap peripheral nerve repair through sustained release of a neurotrophic factor in nonhuman primates. Science Translational Medicine 12(527):eaav7753, 2020. DOI: 10.1126/scitranslmed.aav7753. https://doi.org/10.1126/scitranslmed.aav7753
  15. Lee HH, Lien SE, Alpizar Vargas V, Shultz RB, Laimo FA, Katiyar KS, Cullen DK. Controlled spatial and temporal release of neurotrophic growth factor from genetically modified tissue engineering living scaffolds. Journal of Tissue Engineering 16:20417314251389333, 2025. DOI: 10.1177/20417314251389333. https://doi.org/10.1177/20417314251389333
  16. Sharshakova A, Solovyeva V, Masgutova G, Fattakhova A, Rizvanov A, Sufianov A, Sufianova G, Masgutov R. Contemporary strategies of gene and cell therapy in the treatment of peripheral nervous system injuries and disorders. International Journal of Molecular Sciences 27(5):2335, 2026. DOI: 10.3390/ijms27052335. https://doi.org/10.3390/ijms27052335
  17. Aldali F, Tang L, Yang Y, Huang Y, Li Y, Deng C, Chen H. Peripheral nerve repair: innovations and future directions. Journal of Translational Medicine 24:330, 2026. DOI: 10.1186/s12967-025-07567-z. https://doi.org/10.1186/s12967-025-07567-z